학술논문

Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma.
Document Type
Article
Source
Expert Review of Anticancer Therapy; Jun2023, Vol. 23 Issue 6, p565-571, 7p
Subject
ESOPHAGEAL cancer
SQUAMOUS cell carcinoma
IMMUNE checkpoint inhibitors
NIVOLUMAB
LYMPH nodes
Language
ISSN
14737140
Abstract
Copyright of Expert Review of Anticancer Therapy is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)